FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The time and associated costs (drug, labor, supply) of administering a continuous versus an intermittent i.v. infusion of piperacillin tazobactam were compared. The total labor cost was calculated ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
4d
Hosted on MSNSupernus wins FDA approval for Parkinson’s pump on fourth trySupernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
5mon
News Medical on MSNNew evidence supports continuous infusion for GI cancersFor decades, the most effective treatment for gastrointestinal cancers was a combination of two forms of 5-fluorouracil: the ...
4d
HealthDay on MSNFDA Approves Wearable Infusion Device for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results